Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Nippon Chemiphar Co., Ltd.

http://www.chemiphar.co.jp/english/

Latest From Nippon Chemiphar Co., Ltd.

Consolidation And COVID See Off-Patent Industry Rankings Rewritten

After an extraordinary year that saw demand patterns and the supply chain upended by the COVID-19 pandemic, as well as a major merger that has transformed one of the global off-patent industry’s biggest players, Generics Bulletin’s Top 50 has once again seen significant changes.

Sales & Earnings Biosimilars

Nippon Chemiphar’s Generics Business Continues To Recover

Nippon Chemiphar’s generics business continues to recover after two good quarters back-to-back. The Japanese company took time to stabilize after setbacks due to the adverse effect of National Health Insurance drug price revisions, as well as the impact of the coronavirus pandemic. 

Sales & Earnings Generic Drugs

Nippon Chemiphar Turns The Tide With Increase In Generics Sales

Japan’s Nippon Chemiphar has reported a year-on-year increase in generics sales and net revenues in the first quarter of FY21, after seeing back-to-back underwhelming quarters due to reasons such as recent National Health Insurance drug price revisions, as well as the impact of the coronavirus pandemic.

Japan Generic Drugs

Generics Industry Fails To Match Last Year’s Growth In First Quarter

The generics industry struggled with the prior-year comparison as it saw an expected decline in revenues in the first quarter of 2021, driven by the global impact of the COVID-19 crisis. As a result, the performance of most companies fell short of the numbers reported in Q1 2020. However, a few managed to contradict the trend by reporting growth, either based on the launch of COVID-related drugs or performance in specific geographies. 

Sales & Earnings Coronavirus COVID-19
See All

Company Information

  • Industry
  • In Vitro Diagnostics
  • Laboratory Testing Services
  • Pharmaceuticals
  • Services
  • Pharmaceuticals
    • Generic Drugs
    • Nutraceuticals
  • Medical Devices
    • Diagnostic Equipment & Supplies
    • Diagnostic Imaging Equipment & Supplies
      • Digital Imaging
  • Biotechnology
    • Drug Discovery Tools
      • Molecular Diversity
        • Natural Products
UsernamePublicRestriction

Register